Q&A: Bristol Myers’ Lynelle Hoch on autoimmune CAR-T safety challenges, new patient death

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.